Yu-Kang Tu (Jen-Yu Hung)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 15

Top Topics

Chronic Myeloid Leukemia

Systematic Review

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Journal of personalized medicine

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Ming-Ju Tsai, Yu-Kang Tu, Juei-Yang Ma, Yu-Chen Tsai, Kuan-Li Wu, Mei-Hsuan Lee, Chia-Yu Kuo, Cheng-Hao Chuang, Tai-Huang Lee, Yen-Lung Lee, Chun-Ming Huang, Mei-Chiou Shen, Chih-Jen Yang, Inn-Wen Chong
Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR -Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib. Cancers 15 (7) (2023)
Hsiao-Chen Lee, Chao-Yuan Chang, Kuan-Li Wu, Hung-Hsing Chiang, Yung-Yun Chang, Lian-Xiu Liu, Yung-Chi Huang, Yu-Kang Tu, Ya-Ling Hsu, Yu-Yuan Wu, Ying-Ming Tsai
The Therapeutic Potential of ADAMTS8 in Lung Adenocarcinoma without Targetable Therapy. Journal of personalized medicine 12 (6) (2022)
Tai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, Chiou-Mei Wu, Kuan-Li Wu, Chia-Yu Kuo, Po-Ju Wei, Chin-Ling Chen, Hui-Lin Liu, Yu-Kang Tu, Chih-Jen Yang, Inn-Wen Chong
Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. Journal of clinical medicine 11 (12) (2022)
Chia-Yu Kuo, Ming-Ju Tsai, Yu-Kang Tu, Kuan-Li Wu, Ying-Ming Tsai, Yu-Chen Tsai, Cheng-Hao Chuang, Tai-Huang Lee, Huang-Chi Chen, Chih-Jen Yang, Inn-Wen Chong
Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. Cancers 15 (1) (2022)
Kuan-Li Wu, Yung-Chi Huang, Yu-Yuan Wu, Chao-Yuan Chang, Yung-Yun Chang, Hung-Hsing Chiang, Lian-Xiu Liu, Ying-Ming Tsai, Yu-Kang Tu
Characterization of the Oncogenic Potential of Eukaryotic Initiation Factor 4A1 in Lung Adenocarcinoma via Cell Cycle Regulation and Immune Microenvironment Reprogramming. Biology 11 (7) (2022)
En-Chi Hsu, Kuan-Li Wu, Ying-Ming Tsai, Mei-Hsuan Lee, Ming-Ju Tsai, Chia-Yu Kuo, Yu-Chuan Liu, Fu-Wen Liang, Chih-Jen Yang, Yu-Kang Tu
Real-world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients. The Kaohsiung journal of medical sciences 38 (10) (2022)
Hsiao-Chen Lee, Chao-Yuan Chang, Yung-Chi Huang, Kuan-Li Wu, Hung-Hsing Chiang, Yung-Yun Chang, Lian-Xiu Liu, Yu-Kang Tu, Ya-Ling Hsu, Yu-Yuan Wu, Ying-Ming Tsai
Downregulated ADAMTS1 Incorporating A2M Contributes to Tumorigenesis and Alters Tumor Immune Microenvironment in Lung Adenocarcinoma. Biology 11 (5) (2022)
Chia-Yu Kuo, Ming-Ju Tsai, Yu-Kang Tu, Kuan-Li Wu, Ying-Ming Tsai, Yu-Chen Tsai, Cheng-Hao Chuang, Tai-Huang Lee, Huang-Chi Chen, Chih-Jen Yang, Inn-Wen Chong
Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. Cancers 15 (1) (2022)
Chia-Yu Kuo, Ming-Ju Tsai, Yu-Kang Tu, Kuan-Li Wu, Ying-Ming Tsai, Yu-Chen Tsai, Cheng-Hao Chuang, Tai-Huang Lee, Huang-Chi Chen, Chih-Jen Yang, Inn-Wen Chong
Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. Cancers 15 (1) (2022)
Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen, Yu-Kang Tu, Chih-Jen Yang, Chih-Jen Yang, Inn-Wen Chong
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer. Cancers 13 (8) (2021)
Wei-An Chang, Ming-Ju Tsai, Yu-Kang Tu, Kuan-Li Wu, Ying-Ming Tsai, Yung-Chi Huang, Chao-Yuan Chang, Pei-Hsun Tsai, Ya-Ling Hsu
miR-150-5p-Containing Extracellular Vesicles Are a New Immunoregulator That Favor the Progression of Lung Cancer in Hypoxic Microenvironments by Altering the Phenotype of NK Cells. Cancers 13 (24) (2021)
Meng-Chi Yen, Kuan-Li Wu, Yu-Wei Liu, Yung-Yun Chang, Chao-Yuan Chang, Yu-Kang Tu, Ying-Ming Tsai, Ya-Ling Hsu
Ubiquitin Conjugating Enzyme E2 H (UBE2H) Is Linked to Poor Outcomes and Metastasis in Lung Adenocarcinoma. Biology 10 (5) (2021)
Kuan-Li Wu, Hsiao-Ling Chen, Ying-Ming Tsai, Tai-Huang Lee, Hsiu-Mei Chang, Yu-Chen Tsai, Cheng-Hao Chuang, Yong-Chieh Chang, Chin-Ling Chen, Chih-Jen Yang, Yu-Kang Tu, Inn-Wen Chong
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. Journal of clinical medicine 10 (19) (2021)
Chao-Yuan Chang, Kuan-Li Wu, Yung-Yun Chang, Yu-Wei Liu, Yung-Chi Huang, Shu-Fang Jian, Yi-Shiuan Lin, Pei-Hsun Tsai, Yu-Kang Tu, Ying-Ming Tsai, Ya-Ling Hsu
The Downregulation of LSAMP Expression Promotes Lung Cancer Progression and Is Associated with Poor Survival Prognosis. Journal of personalized medicine 11 (6) (2021)
Yu-Chen Tsai, Hsiao-Ling Chen, Tai-Huang Lee, Hsiu-Mei Chang, Kuan-Li Wu, Cheng-Hao Chuang, Yong-Chieh Chang, Chin-Ling Chen, Yu-Kang Tu, Chih-Jen Yang, Inn-Wen Chong
Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis. Cancers 14 (1) (2021)